# **Resource Summary Report**

Generated by FDI Lab - SciCrunch.org on May 4, 2025

# <u>CT26</u>

RRID:CVCL\_7254 Type: Cell Line

**Proper Citation** 

(RRID:CVCL\_7254)

#### **Cell Line Information**

URL: https://web.expasy.org/cellosaurus/CVCL\_7254

Proper Citation: (RRID:CVCL\_7254)

Description: Cell line CT26 is a Cancer cell line with a species of origin Mus musculus

Disease: Mouse colon adenocarcinoma

Defining Citation: PMID:6992981, PMID:25277546

**Comments:** Breed/subspecies: BALB/c., Derived from sampling site: Colon., Omics: SNP array analysis., Transformant: ChEBI; CHEBI:82373; N-nitroso-N-methylurethane (NNMU).

Category: Cancer cell line

**Organism:** Mus musculus

Name: CT26

Synonyms: CT-26, CT 26, CT-26 WT, CT26.WT

**Cross References:** BTO:BTO:0003630, ChEMBL-Cells:CHEMBL3308079, ChEMBL-Targets:CHEMBL613866, CLS:305178, KCB:KCB 2012007YJ, KCLB:80009, Lonza:1686, NCBI\_Iran:C532, TOKU-E:4093, Wikidata:Q54814707

**ID:** CVCL\_7254

Record Creation Time: 20220427T215526+0000

Record Last Update: 20250420T104931+0000

## **Ratings and Alerts**

No rating or validation information has been found for CT26.

No alerts have been found for CT26.

## Data and Source Information

Source: Cellosaurus

#### **Usage and Citation Metrics**

We found 1752 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Benej M, et al. (2024) The Tumor Microbiome Reacts to Hypoxia and Can Influence Response to Radiation Treatment in Colorectal Cancer. Cancer research communications, 4(7), 1690.

Koh DI, et al. (2024) The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy. Cancer immunology research, 12(4), 491.

Su LY, et al. (2024) Anti-tumor immunotherapy using engineered bacterial outer membrane vesicles fused to lysosome-targeting chimeras mediated by transferrin receptor. Cell chemical biology.

Patel E, et al. (2024) XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies. Molecular cancer therapeutics, 23(4), 421.

Funauchi M, et al. (2024) Tumor cell-expressed lipolysis-stimulated lipoprotein receptor negatively regulates T-cell function. International journal of cancer, 154(3), 425.

Kong H, et al. (2024) Spatial Context of Immune Checkpoints as Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor-Node-Metastasis Stages. Cancer research communications, 4(11), 3025.

Jové V, et al. (2024) Type I interferon regulation by USP18 is a key vulnerability in cancer. iScience, 27(4), 109593.

Yu Q, et al. (2024) Altered epitopes enhance macrophage-mediated anti-tumour immunity to low-immunogenic tumour mutations. Immunology, 173(4), 654.

Liu F, et al. (2023) Nigakinone alleviates DSS-induced experimental colitis via regulating bile acid profile and FXR/NLRP3 signaling pathways. Phytotherapy research : PTR, 37(1), 15.

Wang Z, et al. (2023) Isolation of tumour-reactive lymphocytes from peripheral blood via microfluidic immunomagnetic cell sorting. Nature biomedical engineering, 7(9), 1188.

Zhang H, et al. (2023) Venlafaxine antagonizes the noradrenaline-promoted colon cancer progression by inhibiting the norepinephrine transporter. Cell death discovery, 9(1), 152.

Puig-Blasco L, et al. (2023) Loss of cancer cell-derived ADAM15 alters the tumor microenvironment in colorectal tumors. International journal of cancer, 153(12), 2068.

Sun C, et al. (2023) Immunotherapies targeting neoantigens are effective in PD-1 blockaderesistant tumors. International journal of cancer, 152(7), 1463.

Silver AB, et al. (2023) An engineered immunocytokine with collagen affinity improves the tumor bioavailability, tolerability, and therapeutic efficacy of IL-2. Cell reports. Medicine, 4(11), 101289.

Rossmueller G, et al. (2023) Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic. Molecular cancer therapeutics, 22(5), 555.

Pan X, et al. (2023) KLF12 transcriptionally regulates PD-L1 expression in non-small cell lung cancer. Molecular oncology, 17(12), 2659.

Xiao X, et al. (2023) ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy. Nature communications, 14(1), 2859.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Tumas S, et al. (2023) Engineered E. coli Nissle 1917 for delivery of bioactive IL-2 for cancer immunotherapy. Scientific reports, 13(1), 12506.

Luo F, et al. (2023) Anti-tumor effect of PD-L1-targeting antagonistic aptamer-ASO delivery system with dual inhibitory function in immunotherapy. Cell chemical biology, 30(11), 1390.